A Phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of SION-451 in healthy participants
Sionna Therapeutics, Inc
96 participants
Aug 6, 2024
Interventional
Conditions
Summary
This is a Phase 1, first-in-human (FIH), randomised, double-blind, placebo controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of SION-451 administered as an oral suspension in healthy participants.
Eligibility
Inclusion Criteria7
- Participants must meet all of the following criteria to be included in the study:
- Healthy male or female adult participants aged 18 to 55 years, inclusive, at the time of consent.
- Weight of at least 45 kg and body mass index between 18.0 and 32.0 kg/m2, inclusive, at Screening.
- Participant is willing to abstain from alcohol, caffeine, smoking and nicotine-containing products for 72 hours prior to Day -1 through the duration of the study. Participant is willing to abstain from eating cruciferous vegetables, charcoal-grilled meats, and poppy seeds for 48 hours prior to dosing throughout the duration of the study.
- Participant has read, understood, and voluntarily provided written informed consent
- Participant has an understanding, ability, and willingness to fully comply with study procedures and restrictions.
- Female participants (sex assigned at birth) must be of non-childbearing potential or willing to comply with acceptable highly effective contraceptive requirements (including negative pregnancy tests). Male participants (sex assigned at birth) must be infertile or willing to comply with acceptable highly effective contraceptive requirements.
Exclusion Criteria20
- Participants who meet any of the following criteria must be excluded from the study:
- Participant has clinically significant, in the opinion of the investigator, current or recurrent illness, such as cardiovascular (including but not limited to known structural cardiac abnormalities, family history of long QT syndrome, or cardiac syncope or recurrent, idiopathic syncope), neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine, or psychiatric disease or disorder, or other abnormality which may affect safety or clinical laboratory evaluations.
- Participant has a history of malignancy, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of recurrence for at least 1 year.
- Participant has clinically significant abnormalities, in the opinion of the investigator, on ECG, physical examination, or vital sign assessment at Screening or Day -1.
- Participant has any single reading of QTcF >470 ms (females) or >450 ms (males) at Screening or Day -1.
- Chronic or habitual alcohol (>10 standard drinks per week) or tobacco (>10 cigarettes per week) use or use of recreational drugs (>1 use per month). The Investigator may exclude a participant with lower levels of alcohol, tobacco, or recreational drug use based on discretion and the pattern or history of use.
- Participant is positive for drug screen at Screening or Day -1. Of note, the drug screen does not include cannabis, cotinine or alcohol testing at Screening but does include this testing at study Check-in (Day -1).
- Participant has taken any prescription or over the counter medications within 14 days (or 5 half-lives of the medication, whichever is longer) prior to dosing or requires the use of these medications during the study, including herbal or homeopathic preparations excluding prophylactic doses of vitamin/mineral supplements and occasional paracetamol or ibuprofen, which are allowed.
- Participant has clinically significant abnormalities, in the opinion of the Investigator, at Screening or Day -1 on safety laboratory tests including serum chemistry, haematology, coagulation tests, and urinalysis.
- a. Participant must have an estimated glomerular filtration rate >90 mL/min/1.73 m2 using the CKD-EPI 2021 formula and based on individual body surface area at Screening and Day -1.
- b. Participant must have ALT, AST, alkaline phosphatase, and direct bilirubin less than or equal to the ULN at Screening and Day -1.
- Participant has a positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at Screening. Healthy volunteers who have no evidence of cirrhosis and have completed a curative intent regimen for HCV, with a negative HCV polymerase chain reaction (PCR) test, will not be excluded.
- Participant has used any medication listed on the Flockhart table that is a substrate, inhibitor, or inducer of CYP3A4, or a substrate of CYP1A2 (with the exception of caffeine), CYP2B6, CYP2C8, CYP2C19 or CYP2D6 within 28 days or 10 half-lives (whichever is longer) prior to the planned first study drug administration. Additionally, participants must not have consumed other substances known to be potent inhibitors or inducers of CYP450 such as Seville orange, grapefruit or cranberry juice-containing products and herbal supplements such as St. John’s Wort within 14 days before the planned first study drug administration.
- Participant has used any other prescription or over-the-counter medication that the Investigator judges is likely to interfere with the study or pose an additional risk in participating, within 14 days or 5 half-lives (whichever is longer) or has received any vaccinations within 14 days prior to the planned first study drug administration.
- Participant has received an investigational product within 30 days or 5 half-lives (whichever is longer) of the first study drug administration or will start any other investigational product before the planned End of Study Telephone Contact visit.
- Participant has been treated with an investigational device within 30 days prior to first study drug administration or will start an investigational device study before the planned End of Study Telephone Contact visit.
- Participant has donated or lost greater than 400 mL blood (or plasma) within the last 6 weeks preceding the first study drug administration.
- Participant has known or suspected intolerance or hypersensitivity to the investigational product, or any of the stated ingredients (including OraBlend and hypromellose polymer).
- Females who are breastfeeding or planning to breastfeed within 90 days of the End of Study Visit.
- Participant has an inability to follow a standardised meal schedule and diet or inability to fast, as required during the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is a Phase 1, randomised, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and Pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of SION 451 in healthy participants. Study drug (SION-451 and placebo) will be administered as an oral suspension. This study is comprised of 2 Parts: Part A (SAD) and Part B (MAD). Each study part will include a Screening Period, a Treatment Period, and an End of Study (EoS) visit. Participants to be included in this study will be healthy male and female adults 18 to 55 years of age, inclusive, with no clinically significant concomitant medical conditions and who are not taking any concomitant medications. All potential participants will be screened a maximum of 28 days (Day -28) prior to check-in (Day -1) to assess their eligibility to enter the study and dosing will be initiated on Day 1. Participants will generally be fasted prior to each dose of study drug. Participants in Parts A and B of the study, will be randomised 6:2 to active:placebo, and treatment assignments will be blinded. SAD (Part A) Participants in Part A of the study will be admitted to the Clinical Research Unit (CRU) on Day -1. On the following morning (Day 1), participants will receive a single dose of study drug (active or placebo depending on their randomised treatment assignment) in a fasted state (at least 10 hours pre-dose and 4 hours post-dose). Sentinel dosing will be employed for each Part A dose escalation cohort such that the first 2 participants will be enrolled and randomised to active drug or placebo; if no stopping rules are 1:1 met after 48 hours of monitoring, the remaining participants in the cohort will be randomised. Each cohort will enrol approximately 8 participants randomised 6:2 to active:placebo. Approximately 6 SAD cohorts are planned and dosing will begin at 75mg (Cohort 1) up to 750mg (Cohort 5). Dose escalation decisions will be made by the SRC composed of medically qualified representatives from Sionna, the CRO, and the investigative site (including the Principal Investigator) following review of all available safety data. The SRC will review key safety data (eg, AEs, safety laboratory results, physical examinations, vital signs, ECGs) after completion of each SAD cohort to approve proceeding to the next dose-escalation cohort; where available, PK results from prior cohorts may also be reviewed. No subsequent dose will exceed 2× the dose level of a preceding cohort that has been safe and well tolerated. The dose level for Cohort 6 will also be determined based on SRC review of safety and PK data from previous cohorts. All participants will remain in the CRU until 72 hours following their final dose of study drug (Day 1) for safety monitoring and collection of blood samples for PK analysis. All participants will return to the CRU an EOS visit 7 (+/-1 day) after the last dose of study drug. MAD (Part B) Part B dosing will not begin until the SRC has reviewed the available safety data from at least the first 3 SAD cohorts and determines it is safe to proceed. A unique group of participants will be enrolled in Part B of the study and will be admitted to the CRU on Day -1. On Days 1 through 9, participants will receive a single dose level of study drug (active or placebo based on their randomised treatment assignment) administered twice or three times daily. On Day 10, MAD cohort participants will only receive a morning dose. Participants will fast for at least 10 hours pre-dose and 4 hours post-dose for the first dose on Day 1 and for the last dose given on the morning of Day 10; for all other doses, participants will fast for at least 2 hours pre-dose and 2 hours post-dose. Each cohort will enrol approximately 8 participants randomised 6:2 to active:placebo. The SRC may recommend lower or intermediate dose levels be explored, provided the selected dose or a higher dose has been declared safe and well tolerated in Part A. In addition, the SRC may recommend adjustment of the dose frequency from twice or three times daily based on the available safety and PK data. Approximately 6 MAD cohorts are planned and dosing will begin at 75mg (Cohort 1) up to 750mg (Cohort 5). The dose level for Cohort 6 will be determined based on SRC review of safety and PK data from previous cohorts. Participants will remain at the CRU for at least 72 hours following administration of their last dose (Day 13) for safety monitoring and collection of blood samples for PK analysis. All participants will return to the unit for an EoS visit 7 (±1) days after the last dose of study drug. Clinical facility staff will administer the study drug only to participants included in the study following the procedures set out in the study protocol . Administration of study drugs will be recorded in the appropriate drug accountability records and the electronic case report form (eCRF). Administration of study drug will be verified by a second staff member. Each Participant will be given only the study drug preparation carrying his/her study number.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12624000849594